FDA Commissioner: Patient Safety Must Be Prioritized Over Job Creation
Dr. Hamburg was joined by Paul Glover of Health Canada and Guido Rasi of the European Medicines Agency at the Drug Information Association's 48th annual meeting.
The FDA was recently scrutinized by Congressional members who believe the agency has impeded job creation by shutting down plants with quality control problems. Dr. Hamburg stressed quality concerns, such as glass shards and metal fractures in tobacco products, could not be ignored by the FDA and other regulators.
Mr. Glover added a universal reporting mechanism could more quickly alert regulators about adverse events and promote patient safety around the world.
More Articles on Patient Safety:AHRQ 2011 State Snapshots Spotlight Healthcare Quality, Population Health
© Copyright ASC COMMUNICATIONS 2015. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
New From Becker's Infection Control & Clinical Quality
Merck's Ebola vaccine efficacious in phase 3 study: 5 key pointsRead Now
- Dr. Julie Servoss: A GI tech must-have
- GI society roundtable: Putting together the game plan for potential colonoscopy cuts
- 5 critical steps to developing an ASC risk management program
- Researchers reconstruct ancient virus to enhance gene therapy — 5 notes
- GI physician leader to know: Dr. Jacques Van Dam of USC's Keck School Medicine